Turn Therapeutics (TTRX) Net Income towards Common Stockholders (2024 - 2026)

Turn Therapeutics' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$3.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 449.34% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at -$14.2 million (changed N/A YoY), while the FY2025 annual figure was -$13.9 million, down 146.3% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$3.1 million, down from -$2.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$470237.0 in Q4 2024, with the low at -$7.6 million in Q3 2025.
• The 3-year median for Net Income towards Common Stockholders is -$2.0 million (2024), against an average of -$2.6 million.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders plunged 638.58% in 2025, then slumped 449.34% in 2026.
• Turn Therapeutics' Net Income towards Common Stockholders stood at -$470237.0 in 2024, then slumped by 522.47% to -$2.9 million in 2025, then declined by 7.5% to -$3.1 million in 2026.
• Business Quant data shows TTRX's Net Income towards Common Stockholders at -$3.1 million in Q1 2026, -$2.9 million in Q4 2025, and -$7.6 million in Q3 2025.